Guardant Health(GH) - 2024 Q3 - Quarterly Results

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920 PALO ALTO, Calif. November 6, 2024 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights • Recorded revenue of$191.5 million fo ...